ARCUS BIOSCIENCES INC (RCUS) Stock Income Statement
NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 141.00M | 258.00M | 117.00M | 112.00M | 382.90M | |||
| Operating Expenses | 577.00M | 568.00M | 457.00M | 392.00M | 328.60M | |||
| Research and Development | N/A | 448.00M | 340.00M | 288.00M | 256.30M | |||
| Selling, General, and Administrative Expenses | 116.00M | 120.00M | 117.00M | 104.00M | 72.30M | |||
| Operating Income | -436.00M | -310.00M | -340.00M | -280.00M | 54.20M | |||
| Interest Income/Expense | N/A | 52.00M | 41.00M | 16.00M | 700.00K | |||
| Other Income/Expense | 7.00M | -4.00M | -2.00M | -2.00M | -300.00K | |||
| Non Recurring Items | 0.00 | -20.00M | N/A | N/A | N/A | |||
| Income Before Taxes | -390.00M | -282.00M | -301.00M | -266.00M | 54.60M | |||
| Income Tax | 1.00M | 1.00M | 6.00M | 1.00M | 1.80M | |||
| Net Income | -391.00M | -283.00M | -307.00M | -267.00M | 52.80M | |||
| EBITDA | -426.00M | -300.00M | -332.00M | -274.00M | 58.00M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.20 | -3.14 | -4.15 | -3.71 | 0.71 | |||
| Non GAAP EPS | -4.19 | -3.10 | -4.15 | -3.72 | 0.43 | |||
| Statistics | ||||||||
| Profit Margin | -277.30% | -109.69% | -262.39% | -238.39% | 13.79% | |||
| Operating Profit Margin | -309.22% | -120.16% | -290.60% | -250.00% | 14.16% | |||
All data in USD